Insphero collaborates with the American Laboratory Products Company

Please login or
register
30.07.2018
InSphero’s 3D InSight Diabetes Discovery Platform

Following the receipt of an additional USD 10 million, Insphero has now won American Laboratory Products Company (ALPCO), a leading producer of research and clinical immunoassays as its new partner.

The two companies aim to provide customers with a complete solution to assess beta-cell function in islet microtissue culture models. InSphero’s 3D InSight Diabetes Discovery Platform offers users a comprehensive beta-cell function application suite with all required materials to quantify insulin secretion from 3D InSight Islet Microtissues, including ALPCO’s validated STELLUX Chemiluminescent Insulin ELISA.

InSphero’s 3D InSight platform requires the use of highly sensitive assays that have a broad range and utilize a small sample size to accurately quantify the secretion of insulin and other beta-cell biomarkers from their precious islets,” explains Sean Conley, ALPCO’s president. “Through extensive testing, our STELLUX Chemiluminescent Insulin ELISA proved to meet or exceed the criteria needed for assaying islet microtissue cultures, demonstrating that it is a perfect fit for customers using 3D InSight.”

Burcak Yesildag, InSphero Group Head of Islet Solutions says, “Robust and accurate quantification of insulin secretion from single 3D InSight Islet Microtissues requires a highly sensitive method. We prefer ALPCO’s STELLUXChemiluminescent ELISA because it combines the high sensitivity and broad dynamic range necessary for our model, and requires only a small sample size, thus preserving precious islet material and enabling multi-parametric endpoint analysis.”

ALPCO and InSphero are also currently working to test and validate more STELLUX Chemiluminescent ELISAs to potentially include in the 3D InSight Diabetes Discovery Platform and further promote the advancement of early stage metabolic disease research.

About ALPCO
American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since grown into a premier channel representing over 60 collaborating partners from around the globe. Today, ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care.

(Press release/ran)

0Comments

More news about

InSphero AG

Company profiles on startup.ch

InSphero AG

rss